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At a ﬁrst glance, ribosome biogenesis and chromatin remodeling are quite diﬀerent processes, but they share a common
problem involving interactions between charged nucleic acids and small basic proteins that may result in unwanted intracellular
aggregations. The multifunctional nuclear acidic chaperone NPM1 (B23/nucleophosmin) is active in several stages of ribosome
biogenesis, chromatin remodeling, and mitosis as well as in DNA repair, replication and transcription. In addition, NPM1 plays an
important role in the Myc-ARF-p53 pathway as well as in SUMO regulation. However, the relative importance of NPM1 in these
processes remains unclear. Provided herein is an update on the expanding list of the diverse activities and interacting partners
of NPM1. Mechanisms of NPM1 nuclear export functions of NPM1 in the nucleolus and at the mitotic spindle are discussed in
relation to tumor development. It is argued that the suggested function of NPM1 as a histone chaperone could explain several, but
not all, of the eﬀects observed in cells following changes in NPM1 expression. A future challenge is to understand how NPM1 is
activated, recruited, and controlled to carry out its functions.
1.Introduction
Ribosomebiogenesisandchromatinremodelingarediﬀerent
processes but some parallels can be drawn. Similar to the
deposition ofhistonesonto DNA,ribosomal proteinshaveto
bind ribosomal RNA (rRNA), and it has been assumed that
both processes are prone to aggregation. With regard to size
and charge, histones are reminiscent of ribosomal proteins,
namely, small and basic. Histones can be divided into core
histones and the H1 family of linker histones. Core histones
H2A, H2B, H3, and H4 associate as H2A/H2B dimers and
H3/H4 tetramers to form the histone octamer, that thus
contains two H2A/H2B dimers and a H3/H4 tetramer, that
the DNA is wrapped around forming a repetitive structure
known as the nucleosome. Assembly of histone octamer
complexeswiththehelpofchaperoneswasproposedtobean
ancestral feature of eukaryotes [1]. Histone chaperones are
factors that bind histones and stimulate reactions involving
histone transfer without being part of the ﬁnal product [2].
They can be involved in histone transfer onto DNA (deposi-
tion), oﬀ DNA (eviction), from one chaperone to another,
and ﬁnally histone chaperones could facilitate transfer to
enzymes that use histones as substrates [2]. An emerging
trend is the increasing appreciation for more active roles of
histone chaperones in chromatin remodeling, for instance to
increase transcription rates and facilitate replication [2, 3].
Some chaperones can store histones for a prolonged time
before the actual transfer takes place and histone chaperones
belonging to the nucleophosmin/nucleoplasmin family are
thought to function as “storage platforms” or “sinks” [4].
Some nuclear chaperones may also play a role in
ribosome biogenesis by facilitating interactions between
ribosomal proteins and rRNA, a function ascribed to NPM1,
althoughsolidevidenceforthisfunctionislackingatpresent.
Nevertheless, a fraction of NPM1 is bound to preribosomal
complexes and can aﬀect the rate of ribosome synthesis. But,
NPM1 is also involved in DNA replication, recombination,
transcription and repair. Whereas some of the functions of2 Biochemistry Research International
NPM1 are well established, others have remained less well
deﬁned. So what are the evidences surrounding these diverse
but not necessarily mutually exclusive functions of NPM1?
Moreover, how does the growth promoting activities of
NPM1ﬁtwithitsroleastumorsuppressor?HereIprovidean
updated overview on the functions and interacting proteins
of NPM1 while addressing some of the questions above.
2. Nucleoplasmin Familyof
HistoneChaperones
NPM like proteins (e.g., NPM1-NPM3) have been found
in mammals, ﬁsh, birds, ﬂies but not in bacteria or
yeast (Figure 1). There are some striking diﬀerences in
expression patterns, intracellular localization and func-
tions among the diﬀerent members, but one hallmark
of nucleoplasmins/nucleophosmins is a well-conserved N-
terminal oligomerisation domain [5]. Crystal structures of
the oligomerisation domain from four members of the
nucleoplasmin family have been resolved, namely, nucle-
oplasmin (Np) [6], Drosophila nucleoplasmin-like (dNLP)
[7], human NPM1 [8], and Xenopus NO38/NPM1 [9]. The
cores are in each case a pentamer, with minor diﬀerences
between the diﬀerent structures that could be important
in terms of selectivity for binding partners (Figure 1(b)).
NPM proteins can form a decamer structure by packing two
pentamers on top of each other in a sandwich like structure
and this structure is assumed to be involved in histone
complex binding [9]( Figure 1(c)) .T h ep e n t a m e r sa r en o t
aﬀectedbyDTTindicatingthatcysteinemediateddisulphide
bonds are not critical for the formation of pentamers, hence
they are partially resistant during SDS-PAGE electrophoresis
provided samples are not extensively boiled prior to loading
[10–15].
Nucleoplasmin, a histone storage protein, ﬁrst isolated
from Xenopus laevis oocyte extracts [16, 17]i so n eo f
the most abundant protein in the Xenopus oocyte nucleus
where it is complexed with the maternal histone pool [17,
18]. A nucleoplasmin pentamer may dimerize to form a
decamer, competent for the association of ﬁve H2A/H2B
dimers or ﬁve histone octamers, and nucleoplasmin has the
ability to assemble nucleosomes in vitro [6]. Nucleoplasmin
binds sperm nuclear basic proteins (SNBPs), including
protamines, protamine-like type and histone types [19].
Nucleoplasmin promotes decondensation and remodeling
of paternal chromatin following fertilization by exchanging
SNBPs for histones [20]. The chromatin remodeling activity
of nucleoplasmin at fertilization has been shown to be
dependent on phosphorylation status [21]. Phosphorylation
of nucleoplasmin enhances the H2A/H2B exchange activity
during the decondensation of sperm chromatin and it
also increases the ability of nucleoplasmin to promote
nucleosome assembly in vitro, reviewed in reference [18].
Mammalian nucleoplasmin/NPM2 is expressed only in the
oocytesimilartoXenopus nucleoplasmin.KnockoutofNpm2
in mice have no major eﬀect on meiosis or sperm chromatin
decondensation and the Npm2−/− mice are viable [22].
Nevertheless, Npm2−/− females have reduced fertility or
infertility owing to preimplantation defects and nuclear
abnormalitiesareevidentinNpm2−/− oocytes,includingloss
of heterochromatin and changes in nucleolar organization
[22].
NPM3 shares many characteristics with NPM1 and
NPM2 including an acidic domain and the oligomeriza-
tion region, multiple potential phosphorylation sites and a
nuclear localization signal [5]. NPM3 mRNA is expressed
in many human tissues with high levels in pancreas and
testis [23, 24]. NPM3 protein is localized to the nucleus
and nucleolus in interphase cells. Active rRNA transcription
appears to be required for its nucleolar localization but on
its own does not seem to bind rRNA [25]. NPM3 can bind
histones [26]a n da ﬀect transcription similar to NPM1, but
it was shown that NPM3 lacks intrinsic histone chaperone
activity in vitro [27]. Npm3−/− mice have not been reported
to date but inhibition of NPM3 expression in mammalian
oocytes prohibits paternal chromatin decondensation [28].
It is possible that NPM3 present in mice oocytes could
provide a back up for the loss of NPM2, therefore the sperm
chromatin remodeling function of NPM2 may not be critical
in mammals, as suggested [5]. For an in-depth analysis of
diﬀerent NPM-like proteins and their evolution, I refer the
reader to recent excellent articles on the topic [5, 29, 30].
3.NPM1 ataGlance
3.1. Gene Structure. NPM1 (also known as nucleophosmin,
NO38, numatrin or B23) is the best studied member of the
NPM family and the protein is now directly linked to cancer
development in humans [31]. NPM1 is highly conserved
between humans, rodents, chicken and ﬁsh. Human NPM1
is mapped to chromosome 5q35 and composed of 12 exons.
Two isoforms, besides full length wt NPM1.1, have been
reported, namely, NPM1.2 and NPM1.3 (Figure 2(b)). The
splice variant, NPM1.2, utilizes an alternate 3 -terminal exon
resulting in a shorter protein containing 259 amino acids
[32]. Less is known about expression and function of the
recently deposited isoform NPM1.3 but this isoform lacks
an internal segment in the C-terminal region, with unknown
functional signiﬁcance.
3.2. Protein Domain Structure. NPM1 has a distinct and
unique protein domain structure (Figure 2(a))a n dr e g i o n s
required for oligomerization, chaperone activity, nucleic
acids binding, nuclear localization have been described and
mapped [33–35]. There are a few more interesting features
in the domain organization. The ﬁrst ﬁfteen amino acids
of NPM1 is a methionine rich region but the signiﬁcance
of this region is not clear. It might ensure strong initiation
of translation since the methionine residue codons have
good Kozak sequences [36] and although not an essential
part of the core this methionine rich region may also aﬀect
conformation [36]. NPM1 harbors acidic stretches known
as A1, A2, and A3. These patches could play a role in
charge neutralization by mimicking DNA/RNA. Whereas
it is evident that the NPM1 core region alone (including
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Figure 1: Structure of NPM1. (a) Domain representation of human NPM1, NPM2 and NPM3 proteins. Acidic patches (“A”) are indicated.
(HD: heterodimerization domain, DBD: DNA binding domain, NoLS: nucleolar localization motif). (b) Pentamer structure of Xenopus
laevis xNPM1/NO38 (PDB ID: 1XE0) as visualized in Jalview PDB viewer. (c) Two pentamers of human NPM1 (PDB ID: 2P1B) stacked
in a decameric conﬁguration. (d) Sequence alignment of the core region from diﬀerent NPM1 proteins and NPM-like proteins. Clustal W
was used for alignment and further editing was done with help of Chromas alignment software. The structurally important “AKDE” and
“GSGP” loops are indicated in the ﬁgure as well as the location of conserved L42 and L102 residues (reference to human NPM1). Hs: Homo
sapiens; Mm: Mus musculus; Rn: Rattus norvegicus; Dr: Danio rerio; Gg: Gallus gallus; Xl: Xenopus laevis; Dm: Drosophila melanogaster;
Lp: Lytechinus pictus (sea urchin); Ap: Asterina pectinifera (star ﬁsh).4 Biochemistry Research International
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Figure 2: NPM1 domain organization. (a) Detailed domain representation of human NPM1 highlighting oligomerization, acidic, basic
regions and where A1–A3 denotes the acidic patches (NLS: nuclear localization signal; HD: heterodimerization domain; DBD: DNA binding
domain; NoLS: nucleolar localization motif). (b) Partial sequence alignment of NPM1.1 (wt) and the NPM1.2 and NPM1.3 isoforms
illustrating loss of important parts of NPM1.
Table 1: NPM1 binding proteins.
DNA replication, transcription, and repair
MYC [59]; APE1/Ref-1 [60]; NFKB1 [61]; AR [62]; MIZ1 [63]; AP2α [64]; HEXIM1 [65]; YY1 [66]; CBF-A [67]; IRF1 [68];
MNDA [69]; GCN5 [70]; Histones [37]; C/EBPα [71]; Tpt1 [72]; DOT1L [73]
Cell cycle control
p53 [74]; ARF [75]; MDM2 [76]; pRB [77]; p21 [78]; GADD45A [79]
Ribosome biogenesis
EBP1 [80]; SENP3 and SENP5 [81]; RPL5 [43]; RPS9 [82]; RPL23 [63]; Nucleolin [83]; p120 [50]; NPM3 [25]; USP36 [84];
Nucleostemin [85]; PES1 [86]; TTF1 [87]; FRGY2a/YB1 [88]; NSUN2 [89]
Viral replication
Human T-cell lymphotropic virus Rex [48]
HIV Rev and Tat proteins [47]
Hepatitis delta virus antigens [90]
Hepatitis B virus core protein [91]
Mouse mammary tumor virus p14 env-related protein [92]
Hepatitis C virus core [93]
Japanese encephalitis virus core protein [94]
Adenovirus basic core protein [95]
Apoptosis
Bax [96]; PARP-1 and PARP-2 [97]; PIP3 [98]; GAGE [99]
Stability and splicing of mRNA
hnRNPU [100]; hnRNPA1 [100]; NSP 5a3a [101]
Protein modiﬁcation, synthesis, and degradation
PKR [102]; BRCA1-BARD1 [103]; AKT [104]; Fbw7γ [105]; HLJ1 [106]
Mitotic spindle, cytoskeleton, and centromeres
CRM1 [44]; RPGR and RPGRIP1 [107]; Eg5 [108]; Plk2 [109]; CTCF [110]
the presence of the acidic A2 and A3 patches are required
for histone H2A and H2B binding [37]. The C-terminal
region is unique to NPM1 and contains clusters of basic
amino acids providing localized positive charge followed by
a highly aromatic stretch of amino acids. This region is
implicated in nucleic acid binding [34, 38], ATP binding
[39], histone transfer [37], ribonuclease activity [35]a n d
nucleolar localization [40, 41].
3.3. Cellular Localization. NPM1 is a nucleocytoplasmic
shuttling protein [42] and motifs for nuclear import as well
as nuclear export have been described. The ability of NPM1
to shuttle is critical for several of its postulated functions
including nuclear export of ribosomal protein L5 [43]a n d
c o n t r o lo fc e n t r o s o m ed u p l i c a t i o n[ 44]. NPM1 may assist
small basic proteins in their transport to the nucleolus
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Figure 3: NPM1 is a multifunctional histone binding protein.
NPM1 can aﬀect DNA replication, repair and transcription by
interacting with the components of chromatin such as histones
and chromatin remodeling proteins. NPM1 is also required for a
controlled progression through mitosis and NPM1 can promote
ribosome biogenesis. These eﬀects may arise through the ability
of NPM1 to bind histones at the centromeres or in the nucleolus,
respectively.
basic viral and nucleolar proteins Rev [47], Rex [48], Tat
[49] and p120 [50] and promote their nucleolar localization
(Table 1). NPM1 is a predominantly nucleolar protein,
however, a fraction can also be detected in the nucleoplasm.
NPM1 has a dynamic localization during mitosis and is
observed in nucleolar remnants, at the perichromosomal
layer and at the mitotic spindle pools [51, 52]. Within the
nucleolus,NPM1isenrichedinthegranularcomponentthat
containsmaturingpreribosomalparticles[53].Thesequence
motifs and molecular mechanisms involved in mediating
nucleolar localization of NPM1 are not understood in detail
but experimental evidence points out that several regions in
the protein are required. Mutations in NPM1 that are pre-
dicted to disrupt both the monomer and oligomer structure
markedly impair nucleolar accumulation [54]. In addition,
two conserved tryptophan residues, W288 and W290, are
required for NPM1 nucleolar localization, presumably by
facilitating NPM1 binding to nucleic acids by providing a
propersecondarystructure[55].Recently,residuesK263and
K267 were shown to be functionally required for NPM1’s
localization to nucleoli as well as its protein stability [56,
57]. A functional nuclear localization signal is also needed
[41], but some confusion in the literature exists concerning
what exact motif in the central domain that is required for
nuclear localization [40, 41]. NPM1.2 isoform is present in
cells at low levels and is detected both in the cytoplasm
and nucleoplasm further supporting the notion that the
C-terminus of NPM1 contributes to nucleolar localization
[58].
3.4. Protein Function In Vivo. Knockout of Npm1 in mice
leads to unrestricted centrosome duplication, genomic
instability and impaired ribosome biogenesis [111, 112].
Npm1−/− mice display aberrant organogenesis, in particular
the forebrain does not develop properly. The mice die
between embryonic day E11.5 and E16.5 due to anemia
resulting from severe defects in haematopoiesis [112]. How-
ever, mouse embryo ﬁbroblasts lacking both p53 and Npm1
are viable and can proliferate in vitro, indicating that Npm1
is not strictly essential for cell growth and proliferation
[111, 112]. It is also interesting that Npm1−/− embryos have
a later timepoint of lethality compared to mouse embryos
with ribosomal protein loss of function [113] suggesting an
important but nonessential function of NPM1 in ribosome
synthesis.
3.5. Posttranslational Modiﬁcations of NPM1. NPM1 protein
is extensively modiﬁed by phosphorylation, acetylation,
ubiquitylation, and SUMOylation. By studying the related
protein nucleoplasmin we have learnt that phosphorylation
is required for the functionality of the nucleoplasmin
core domain in binding basic proteins and decondensating
sperm DNA [21, 114]. From studies on nucleoplasmin
we can therefore presumably learn more about NPM1
but so far, the regulation of NPM1 by phosphorylation is
not well understood. NPM1 is recognized as a nucleolar
phosphoprotein and several kinases, for instance casein
kinase 2 (CKII) [115], polo-like kinase 2 (Plk2) [109], CDC2
[116] and cyclin E/CDK2 complex [117] can phosphorylate
NPM1. Phosphorylation of NPM1 is likely to control aspects
of function, localization and oligomerisation and could
be related to nucleolar function and progression through
mitosis [118]. Phosphorylation of NPM1 could also impinge
on ribosome biogenesis by increasing NPM1’s binding
aﬃnity to ribosomal components. For instance, phospho-
rylation by CKII enhances binding to the NLS sequences
derived from the SV40 large T antigen and HIV Rev
[46, 115].
A ﬂurry of papers 2008-2009 revealed an intricate series
of interactions taking place between NPM1, the ARF tumor
suppressor and the SUMO-pathway. Small Ubiquitin-like
Modiﬁer (SUMO) proteins are covalently attached to other
proteins to modify their function in diverse cellular pro-
cesses, such as apoptosis, intracellular transport, transcrip-
tional regulation, protein stability and DNA damage repair.
TheSUMO-tagisremovedfromitsproteintargetbySUMO-
deconjugating protease (a k a sentrin-speciﬁc protease or
SENP). SENP3 and SENP5 are localized within nucleoli
and bind NPM1 and thus NPM1 may control the SUMO
pathway [119]. Knockdown of either NPM1 or nucleolar
SENPs presents with similar ribosome biogenesis defects
[119]. NPM1 itself is actually SUMOylated [120] although
the site(s) remains a matter of debate and SUMOylation of
NPM1 may aﬀect localization and survival pathways [121].
SENP3 can remove SUMO from NPM1 [81, 122]. Inter-
estingly, it is now realized that the ARF tumor suppressor
promotes SUMOylation of several of its interacting proteins
including NPM1 [123]. Mechanistically, ARF promotes the
turnover of SENP3 protein [123]. NPM1 is also ubiqutinated
[54, 75, 103]. USP36 is a deubiquitylating enzyme that
removes ubiquitin from NPM1 leading to stabilization of
NPM1andimprovednucleolarfunction[84]whiledepletion
of USP36 impairs ribosome biogenesis. Interestingly, NPM16 Biochemistry Research International
itself can target USP36 to nucleoli by direct binding [84].
Thus, interactions between NPM1, ubiquitin and SUMO




NPM1 binds denatured protein substrates, a hallmark of
chaperones. Indeed, one established property of NPM1 is
its ability to prevent aggregation and thermal denaturation
of some proteins in vitro [124]. Because NPM1 was found
associated with preribosomes it was initially thought of as
a ribosome chaperone or assembly factor. In support of
this notion, a fraction of soluble NPM1 is associated
with preribosomal particles, in particular 60S [43]. NPM1
facilitates cleavage of ribosomal RNA in vitro and acts
as an endoribonuclease for the maturing rRNA transcript
[13, 125]. Knockdown of NPM1 using siRNA impairs
processing of prerRNA to mature 28S [75]. Moreover,
blocking NPM1 nucleocytoplasmic shuttling inhibits ribo-
some subunit export resulting in a decrease in cell growth
rate, implicating NPM1 also in preribosome export [126].
NPM1 interact directly with a subset of ribosomal proteins
including RPL5 [43], RPS9 [82], and RPL23 [63]. NPM1
forms a complex with NPM3, and NPM3 was shown to
negatively regulate NPM1 during ribosome biogenesis [25].
ItisnoteworthythatNPM1variantslackingthenucleic-acid-
binding domain also inhibit ribosome biogenesis similar to
NPM3. In summary, NPM1 promotes cell growth and pro-
liferation by supporting several distinct stages in ribosome
biogenesis.
NPM1 can assemble nucleosomes in vitro and decon-
dense sperm DNA similar to nucleoplasmin [37, 95], and
NPM1 was suggested to be a histone chaperone in the
nucleolus [9]. As mentioned NPM1 associates with rDNA
and depletion of NPM1 or expression of a dominant
negative NPM1 mutant lacking histone chaperone activity
leads to a decrease in rDNA transcription [127], although
these eﬀects have not consistently been observed by others
[111, 128, 129]. Interestingly, expression of NPM3 represses
the ability of NPM1 to assemble nucleosomes in vitro
[27], similar to the negative regulation of NPM1 function
by NPM3 seen during ribosome biogenesis. Is it possible
that these regulatory functions are two sides of the same
coin?
Identiﬁcation of the nucleolar p14ARF/p19Arf (hence-
forth ARF) tumor suppressor as a major NPM1 binding
partner ignited interest in the function of NPM1 in the
nucleolus [75, 128, 130]. Enforced expression of ARF
blocks NPM1 nucleocytoplasmic shuttling [128], increases
degradation of NPM1 protein and reduces 28S rRNA
processing [75]. Under normal conditions, NPM1 promotes
the nucleolar localization and stability of ARF, but whether
NPM1 also can block ARF functions remains controversial
[131, 132]. It was argued that under normal conditions
NPM1 mainly act to promote nucleolar localization of ARF
[133]. Interestingly, other groups have found that ARF
reduces protein synthesis by inhibiting polysome formation
[129], and that ARF binds to rDNA to interfere with
transcription [134]. These are interesting ﬁndings given that
NPM1 binds to the rDNA gene promoter and plays a role
in ribosome nuclear export. However, ARF binds to other
targets than NPM1 in the nucleolus [130] and it is therefore
unlikely that all the eﬀects of ARF is funneled through
NPM1. One problem in these types of studies are possible
indirect eﬀects stemming from activation of stress responses,
such as p53 induced cell cycle arrest, that in some settings
could complicate the interpretation of cell growth data (“the
chicken and the egg problem”). A second problem could
involve incomplete NPM1 knockdown in those experiments
thatrelyonRNAigiventhatNPM1isanabundantandstable
protein.
5. NPM1 Functionsin DNA Replication,
TranscriptionandRepair
NPM1 has been implicated in the processes of DNA repli-
cation, recombination, transcription and repair, reviewed in
[31]. And, as mentioned, NPM1 interacts with histones H3,
H4, H2A and H2B. NPM1 may participate in chromatin
remodeling related events by aﬀecting the assembly of nucle-
osomes, or regulate the modiﬁcation of histones through
the recruitment of histone modifying enzymes. Interestingly,
nucleolin (C23), a major nucleolar protein has also been
implicated in DNA replication and transcription in analogy
with NPM1 [135], although nucleolin and NPM1 have no
structural similarity.
5.1. DNA Replication. NPM1 binds retinoblastoma protein
(pRB) and synergistically stimulates DNA polymerase alpha
activity in vitro and may therefore inﬂuence DNA replication
processes [77, 136]. In addition, NPM1 can also stimulate in
vitro replication of adenoviral DNA [95]. Another example
of a histone chaperone involved in replication is ASF1
that preferentially localizes to active DNA replication forks
[137].
5.2. DNA Transcription. NPM1 has been directly impli-
cated in gene transcription in several ways. First, NPM1
interacts with c-Myc through binding at c-Myc promoters
facilitating RNA pol II driven transcription [59]. NPM1
regulates Myc protein turnover as well and may therefore
directly impact on cell growth and transformation during
tumor development [105]. Second, NPM1 can interact with
HEXIM1, a regulator of RNA pol II transcription, to facil-
itate transcription [65]. Third, combination of acetylation
on core histones and NPM1 itself enhances transcription
rates [138]. Acetylation of NPM1 (Ac-NPM1) leads to
disruption of the nucleosome and transcriptional activation.
This indicates a novel and more active role of NPM1
in chromatin remodeling [138]. Ac-NPM1 is preferentially
found in the nucleoplasm in association with RNA poly-
merase II and the increase in Ac-NPM1 seen in cancer
could be of mechanistic importance [139]. On the other
hand, NPM1 binds GCN5 during mitosis to inhibit GCN5Biochemistry Research International 7
mediatedacetylationoffreeandmono-nucleosomalhistones
[70]. Fourth, NPM1 act as a corepressor or coactivator
of transcription by binding to YY1, IRF1, p53, NF-κB
and other transcription factors (Table 1). For example, it
was shown that NPM1 participates in the transcriptional
response to retinoic acid in myeloid cells [64]. During
retinoic acid induced diﬀerentiation, NPM1 forms a com-
plex with activating protein transcription factor 2α,a n d
performs a corepressor function through recruitment of
histone deacetylases [64]. Fifth, and of particular interest,
are the ﬁndings that NPM1 is involved in the regulation
of RNA pol I transcription in the nucleolus [127], and
is critical in mediating induction of rDNA transcription
factor TAF(I)48 [140]. Modulation of RNA pol I tran-
scription could be a critical activity of NPM1 because
changes in rDNA transcription is an important molecular
alteration in cancer cells [141]. RNA pol I activity is tightly
controlled by several tumor suppressors and oncogenes
such as p53 and c-Myc, respectively [142]. Because both
c-Myc and NPM1 bind to nucleolar rDNA chromatin and
can stimulate RNA pol I transcription [127, 143, 144],
it is likely that overexpression of NPM1 facilitates c-Myc
driven rRNA synthesis, similar to how NPM1 facilitate c-
Myc function at RNA pol II controlled promoters. Such
a mechanism could be relevant to consider when thinking
about how NPM1 contributes to cell growth and oncogenic
transformation. Binding of NPM1 to nucleolar chromatin
requires, somewhat surprisingly, the RNA binding activity of
NPM1 and indirectly the nucleolar transcription factor UBF
[145]. Moreover, NPM1 facilitates nucleolar localization
of the RNA polymerase I transcription termination factor
(TTF-1) [87]. In summary, several lines of evidence point
toward a supporting role for NPM1 in RNA pol I and II
transcription.
5.3. DNA Repair. DNA strand breaks trigger activation of
cellular pathways resulting in a DNA damage response and
DNA repair. A DNA strand break results in global and local
changes in chromatin together with activation and recruit-
ment of several repair and signaling factors. Upon sensing
DNAdamage,orintheinitiationofDNArepairitself,NPM1
translocatesfromthenucleolustothenucleoplasmandbinds
chromatin [146]. In particular a pool of phosphorylated
NPM1 is recruited to IR-induced DNA damage foci [147].
Inhibition of rDNA transcription or rRNA processing, in
the absence of DNA damage, also often provokes rapid
translocation of the otherwise predominantly nucleolar
NPM1 protein to the nucleoplasm [148, 149] and by this
change in localization NPM1 may then functionally interact
with diﬀerent cellular pathways. It is interesting that NPM1
mRNA and protein was found to be signiﬁcantly induced
following UV-induced DNA damage [150] and coupled
with an increase in NPM1 expression there was enhanced
RNA binding activity [151]. Enforced NPM1 expression in
turn renders cells more resistant to UV-induced cell death
[152]. It is conceivable that NPM1 could function as a
histone chaperone under, or following, repair of DNA strand
breaks. One example of a histone chaperone with a similar
function already established is yeast CAF1 that mediates
histone H3-H4 assembly during nucleotide excision repair.
CAF1 is critical in chromatin assembly during double strand
break repair but is not strictly needed in the repair process
itself [153]. It would therefore be relevant to investigate
if the NPM1 mediated prosurvival eﬀect can be explained
by a histone chaperone function active in the DNA repair
process.
6. What Is the Functionof NPM1 at
theMitoticSpindle?
The mitotic spindle includes the spindle microtubules, an
array of associated proteins, and the metaphase centrosomes
also present at the spindle poles. At the spindle poles, micro-
tubules are nucleated by the centrosomes while the spindle
ﬁbers are the structures that separate the chromosomes
into the daughter cells during cell division. Failure of
spindle assembly can lead to spindle checkpoint activation
and if not properly regulated may result in aneuploidy.
Npm1 heterozygosity in mice led to unrestricted centrosome
duplication and genomic instability [111, 112]. Interestingly,
afractionofNPM1proteinisdetectedatthemitoticspindles
pool during metaphase, easily detected using conventional
immunoﬂuorescence microscopy [52]. It should be pointed
out that there are other nucleolar proteins at the mitotic
spindles such as nucleolin and ﬁbrillarin, meaning that
NPM1 being a nucleolar protein at the spindle is not in
a unique position. At the spindles, NPM1 colocalizes with
NuMA (nuclear mitotic apparatus protein) [52]. The spindle
pool bound form of NPM1 is modiﬁed, presumably phos-
phorylated, as indicated by migration shifts in immunoblots
[52] .N P M 1m a yp l a yam o r ed i r e c tr o l ei nc e n t r o s o m e
duplication in some cells given evidence that NPM1 asso-
ciates with the unduplicated centrosome in interphase and
is released by cdk2/cyclin E mediated phosphorylation on
NPM1 residue Thr199 leading to initiation of centrosome
duplication [117]. Other investigators have not been able
to detect NPM1 at the centrosome in interphase cells
using proteomics or immunoﬂuorescence [154], although it
should be taken into consideration that the immunogenic
epitopes and conformation of centrosome bound NPM1
could be diﬀerent [155]. In mice, phosphorylation of Npm1
Thr198 was shown to occur throughout the cell cycle and the
cell growth and proliferation rates were similar to wt NPM1.
This suggests that phosphorylation of Npm1 Thr198 is not a
critical event for normal cell proliferation in mice [156].
Centromeres (not to be confused with centrosomes)
are the chromosomal domains that control the mitotic
behavior of chromosomes. NPM1 also associates with a
CENPA (Centromere protein A) containing complex [157].
CENPA encodes a histone H3 related histone fold domain
a n dC E N P Ai sap r e s u m e dc o m p o n e n to fam o d i ﬁ e d
nucleosome-like structure in which it replaces histone H3.
The ﬁnding of NPM1 in complex with CENPA impli-
cates NPM1 also in centromere control. Recent studies
conﬁrmed NPM1 in these complexes but did not ﬁnd
any evidence for a major function of NPM1, although8 Biochemistry Research International
knockdownofNPM1wasnotcompleteinsomeexperiments
[158, 159]. Nevertheless, in rapidly growing HeLa cells,
the depletion of NPM1 resulted in mitotic arrest due
to spindle checkpoint activation and p53 induction and
these cells showed signs of defects in mitotic spindle and
centrosome formation [160]. Data taken together suggest a
supporting histone chaperone function mediated by NPM1
involving centromeric chromatin. Interestingly, depletion of
nucleolin results in growth arrest, increased apoptosis and
numerous nuclear alterations, multipolar spindles together
with defects in centrosome duplication [161] very simi-
lar to the inactivation of NPM1. What makes nucleolin
interesting in this context is that it also functions as a
histone chaperone [162]. To understand the dual function
and localization of NPM1, as well as nucleolin, remains a
challenge.
7.NPM1 and Cancer
NPM1 is clearly having both growth promoting and tumor
suppressive functions. Overexpression of NPM1 enhances
celldivisionandcellgrowthpresumablythroughstimulatory
eﬀects on rDNA transcription, ribosome subunit export
and DNA replication during S-phase. A transforming role
for NPM1 was observed in NIH3T3 cells [68]a n do v e r e x -
pression of NPM1 could possibly promote oncogenesis by
interfering with the activation of p53 by ARF. Similar to
oncogenes, such as Ras, it was found that NPM1 overex-
pression induces cellular senescence in human ﬁbroblasts
[74]. The level of NPM1 is generally elevated in tumor
c e l l sc o m p a r e dw i t hn o r m a lc e l l s .I n c r e a s e dl e v e l so fN P M 1
may at least in part reﬂect a higher growth rate and an
increased demand for ribosome biogenesis in cancer cells
[163] and NPM1 is induced when B-cells, T-cells and Swiss
3T3 cells are stimulated with various mitotic agents [164–
166]. NPM1 is overexpressed in many types of major human
solid tumors including, but not limited to, tumors of the
thyroid [167], brain [168], liver [169] and prostate [62].
NPM1 has been shown to be a target of oncogenic Myc
and NPM1 mRNA can be directly induced by Myc through
binding to the NPM1 promoter [170]. The ability of NPM1
to suppress apoptosis and to promote DNA repair may play
a signiﬁcant prosurvival role during tumor development.
There is however no solid evidence yet demonstrating that
(wt) NPM1 is acting as a bona ﬁde proto-oncogene in vivo,
when overexpressed.
Disruption of the NPM1 gene by translocation or
heterozygous deletion is found in human hematopoietic
malignancies [171], such as acute promyelocytic leukemia
(APL), anaplastic large cell lymphoma (ALCL), and in
premalignant myelodysplastic syndromes (MDS), reviewed
in [31, 171]. Interestingly, translocations occur in the
NPM1 N-terminal region where it fuses to diﬀerent part-
ner genes, such as anaplastic lymphoma kinase (ALK),
retinoic acid receptor α (RARα), or myeloid leukemia
f a c t o r1( M L F 1 )i nA L C L ,A P La n dM D Sr e s p e c t i v e l y .I n
these malignancies, NPM1 contributes to tumor develop-
ment by activating the oncogenic potential of the fused
protein partner, that is, ALK, RARα,o rM L F 1[ 172, 173].
Furthermore, loss of one allele of NPM1 is frequently
observed in patients with de novo and therapy-related MDS
[31]. The signiﬁcance of NPM1 as a cancer gene was
somewhat dubious because it was thought that the NPM1
part (of the fusion protein) was only used an essential
dimerization interface. For instance, in the case of NPM1-
ALK, the transforming capacity correlates with an ability to
form oligomers and NPM1-ALK unable to form oligomers
(dimerize) is nontumorigenic [172]. This unclear role of
NPM1 would change however, as it in 2005 was found
that one-third of adult acute myeloid leukemia (AML)
cases display aberrant cytoplasmic expression of NPM1 with
mutations occurring in the exon-12 of NPM1, therefore
directly implicating NPM1 as a cancer gene [174]. Analysis
and clinical studies regarding NPM1c+ AML has recently
been reviewed extensively and will not be covered further
[175].
8. NPM1 as a Tumor Suppressor
NPM1 is acting as a haploinsuﬃcient tumor suppressor in
blood cells [176]. First, loss of NPM1 destabilizes the ARF
p r o t e i nt h a to c c u r si np a r a l l e lw i t haf a i l u r eo fA R Ft o
properly localize to nucleoli [111]. Decreased levels of ARF
means increased rate of oncogenic transformation of mouse
ﬁbroblasts because ARF is critical to activate p53 in response
to oncogene activation in mice [111, 177]. The notion that
NPM1 is a critical caretaker of ARF is also supported by the
fact that ARF is delocalized and functionally handicapped
in cells expressing AML derived oncogenic NPM1c mutants
[178, 179]. It should be mentioned that NPM1 regulates
nucleolar localization of Fbw7γ isoform and that NPM1c has
lost also this function leading to increased levels of MYC
[105], given that MYC degradation requires Fbw7γ [180].
TheintricatedynamicsoftheARF-NPM1-Mycnetworkhave
been reviewed elsewhere in greater detail [181]. Second,
NPM1 heterozygosity results in genomic instability as shown
by aneuploidy, increased centrosome numbers and DNA
damage checkpoint activation that in a secondary stage
enhances the rate of oncogenic transformation both in vitro
and in vivo.I nf a c t ,Npm1+/− mice often develop hema-
tological malignancies following on a condition resembling
myelodysplasia [112].
Disturbances in nucleolar or ribosomal function are
known as nucleolar stress or ribosomal stress and are often
associated with p53 tumor suppressor pathway activation
[182]. Defects in the ribosome biogenesis machinery often
presents with bone marrow failure and increased cancer
risk. One notable syndrome is Diamond-Blackfan anemia
(DBA) caused by mutations in ribosomal proteins (RPS19,
RPL11, RPL5 and others) leading to defective 40S or
60S ribosomal subunit production with elevated risk of
leukemia and osteosarcoma [183]. As mentioned earlier,
inactivation of nucleolar proteins NPM1 and nucleolin also
leads to mitotic spindle defects, genomic instability and
accumulationofDNAdamagethatinturnactivatesp53.The
extent of genomic instability in DBA patients is not clear.Biochemistry Research International 9
The point being, it is not entirely clear if reducing levels of
NPM1 activates a DNA damage response, a nucleolar stress
response, or both and it could be of relevance to further
investigate this.
In summary, loss of one allele of NPM1 is one step closer
to cancer but it is also worth noting that NPM1 has not been
shown to repress genes involved in cell cycle progression,
induce apoptosis in response to cell damage, or to induce cell
cycle arrest following DNA damage. Therefore, NPM1 is not
your “typical” tumor suppressor gene. Rather, NPM1 acts as
acontextdependenttumorsuppressor,thatisdownstreamof
the cell cycle machinery and expression level and localization
of the protein is of major importance.
9. Mechanisms of NPM1 Nuclear Export
Discovery of the NPM1c mutant in AML, which is a com-
bined gain-of-function (nuclear export) and loss of function
(nucleolar localization) mutant, represents a fundamental
breakthrough in understanding the molecular pathogenesis
o fas u b s e to fA M Lc a s e s[ 174]. NPM1c utilizes a Crm1-
mediated nuclear export mechanism through a frameshift
mutation resulting in the creation of a functional nuclear
export signal (NES) that combined with other amino
acid substitutions is working to prevent NPM1c nucleolar
localization [184]. Related to the work on NPM1c, has
been the parallel hunt for endogenous NES in NPM1 and
two groups have found diﬀerent candidate NES within
the NPM1 oligomerization domain. One motif is the 42-
LSLRTVSL-49sequenceinhNPM1,whereinmutationsL42A
and L44A block NPM1 nuclear export [43]. Similarly,
introducing the L102A mutation within the second NES
94-ITPPVVLRL-102 motif blocks NPM1 nuclear export
[44] and interestingly, introducing the L102A mutant also
prevents NPM1c shuttling. An alternative expanded model
would take into consideration the structure of NPM1 core.
Presumably, mutations introduced in critical loop residues
within the oligomerization domain leads to a collapse and
a failure to maintain the proper structure of the monomer
[54]. Other mutations could impair the conformation
or disrupt the hydrophobic thermostable core of NPM1
while leaving the monomeric structure relatively unaﬀected.
Residues L102, L42 and L44 (reference to human NPM1)
are all highly conserved residues in the entire nucleoplasmin
family (Figure 1(d)). Conceivably, some NPM1 core mutants
that have lost structural and/or functional properties will
likely also aﬀect nuclear export. In other words, NPM1
m u t a n t sw i t hs t r u c t u r a ld e f e c t sm i g h tf a i lt ou n d e r g oe x p o r t
depending on the association with other cellular factors in
combination with conformational changes. This model can
easily be tested by further mutagenesis of conserved residues
within the NPM1 core. The availability of the NPM1 core
structure allows also for in silico prediction of mutations
in terms of structural eﬀects to some extent [54]. Hence,
the analysis of NPM1 nuclear export should take structural
eﬀects into consideration and more remains to be discovered
about NPM1 nuclear export.
10.TargetingNPM1 inCancer
Under the assumption that high levels of NPM1 makes
cancer cells addicted to it, knocking down NPM1 using
RNAi or small molecule inhibitors could block cell growth.
Inhibition of NPM1 in cancer cells but not in normal cells
is therefore an attractive, but still theoretical, therapeutic
a p p r o a c h .R e t r o v i r a lH I Ve n c o d e dR e vi sas m a l lb a s i ca n d
cytotoxic protein with a predominantly nucleolar localiza-
tion, similar to ARF. A Rev derived peptide that binds to
NPM1withhighaﬃnityinterfereswithNPM1function.The
authors showed that NPM1’s ability to transactivate a PCNA
promoter construct was impaired by this Rev peptide [185].
Another peptide is CIGB-300 (P15-TAT), an anticancer
peptide that can bind NPM1 and prevent CK2 driven
phosphorylation leading to nucleolar breakdown and cancer
cell apoptosis [186]. An interesting nonpeptide compound
is avrainvillamide, an alkaloid, that targets residue C275
in human NPM1 and also induces p53 activity in cells
[187].
What about small molecules that inhibit NPM1 oligom-
erization? The compound NSC348884 is a putative NPM1
small molecule inhibitor that disturbs NPM1 oligomer
formation and induces p53 that is followed by apoptosis
in cancer cells [188]. NSC348884 acts by disrupting a
hydrophobic pocket required for oligomerization. In a
similar study to indentify inhibitors of NPM1, Jian et al. used
a SELEX to search for RNA aptamers that bind NPM1 [189].
They identiﬁed a number of RNA aptamers that bound
the central region of NPM1 resulting in disturbed NPM1
oligomerization, nucleolar delocalization and increased sen-
sitivity to apoptosis [189]. Studies in mice indicates a
tumor suppressor role for NPM1 as discussed and therefore
more studies are needed in order to clarify the potential
usefulness of the above mentioned strategy considering then
the complexity of NPM1.
11. Other Functions of NPM1
Undoubtedly NPM1 is a multifunctional protein that has
founditswayintomostchaptersinthecellbiologytextbook.
NPM1 was recently implicated in neural and hematopoietic
stem cell ﬁtness [190, 191], mRNA splicing and stability
[192, 193], and NPM1 may even act as an alarmin in the
immune system [194]. NPM1 was also found to be a nuclear
PIP3 receptor, and the PIP3-NPM1 complex mediates the
antiapoptotic eﬀe c to fn e u r a lg r o w t hf a c t o r( N G F )t h r o u g h
inhibition of caspase activated DNase [98]. There are
several other NPM1 associated proteins than those enlisted
in Table 1, but that remains less well characterized. In
proteomics studies for instance, NPM1 was found associated
with numerous ribosomal proteins and RNA/DNA helicases
[82]. In addition, NPM1 was earlier found to associate
with CDC14 (involved in centrosome organization), SNF2
(chromatin remodeling), Nup98 (nuclear pore) and CENPF
(centromere protein F) [195].
There are also two interesting activities of nucleoplasmin
that could be related to NPM1. First, nucleoplasmin can10 Biochemistry Research International
decondense chromatin in undiﬀerentiated F9 mouse cells
through epigenetic changes that involves histone modi-
ﬁcations and release of heterochromatin proteins [196].
Through this function, nucleoplasmin enhances activation
of oocyte speciﬁc genes in these mouse cell nuclei when
nuclei are injected into frog eggs [196]. Second, apoptotic
chromatin condensation can be regulated by nucleoplasmin
[197]. Both the reprogramming and the apoptotic functions
of nucleoplasmin are very interesting and it would be signif-
icant to investigate if NPM1 could have related functions.
12. Conclusions
As enlisted in this paper, NPM1 participates in a number
of cellular processes including multiple aspects of gene
expression and certain modiﬁed forms of NPM1 seem to
play an active in role in RNA pol II transcription. NPM1
also interacts with a number of proteins at the mitotic
spindle as well as in the nucleolus. A histone chaperone
functionprovidedbyNPM1ispresumedtobeofimportance
at each cellular location but exactly how NPM1 facilitates
transcription, replication and repair remains elusive. The
main function of NPM1 at a given moment could also be
determined by the cell cycle stage. Hence, NPM1 may prefer-
entially promote ribosome biogenesis in G1, facilitate DNA
replication during S-phase while supporting chromosome
segregationinmitosis(Figure 3).Whatwenowhavetobetter
understand is how NPM1 is recruited and controlled at
these diﬀerent “activity stations” in the cell. In this regard,
the recent ﬁnding that phosphorylated NPM1 (T199-p) is
speciﬁcally recruited to DNA damage sites is particularly
interesting [147].
Ample amounts of data show how NPM1 participates in
multiple steps in ribosome synthesis, but it is not easy to
understand how NPM1 can modulate rDNA transcription,
rRNA processing and export of the ribosome at the same
time. Because these processes most likely are coupled, but
unclear how, it will not be straightforward to dissect the
functional role of NPM1 at each stage of ribosome biogen-
e s i s .O fc o u r s e ,af u n c t i o no fN P M 1o nn u c l e o l a rc h r o m a t i n
does not exclude strictly separate later-stage functions in
ribosome assembly and export given that NPM1 binds
both RNA and ribosomal proteins. The same problem have
surrounded nucleolin, being implicated in several ribosome
biogenesis steps (rDNA transcription, rRNA processing and
assembly) and associated with histone chaperone properties
[162]. It now appears that one of the key roles of nucleolin is
to permit transcription of rDNA genes [135]. Further studies
on the role of NPM1 in ribosome biogenesis are needed to
clarify its function. Especially, how NPM1 could contribute
to cellgrowth and transformation by cooperating with onco-
genes in the regulation of rDNA chromatin deserves more
attention. We also need to obtain a better understanding of
the general mechanisms of rDNA transcription and rRNA
processing in human cells. Such eﬀorts are in part hampered
by current limitations in relevant assays to measure and
monitor loading of ribosomal proteins onto RNA and the
kinetics of rRNA processing.
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